Davidk Sim News Today : Breaking News, Live Updates & Top Stories | Vimarsana

BusinessWorld
February 17, 2021 | 11:44 am
Dapagliflozin has been approved by the Food and Drug Administration (FDA) to treat heart failure in adults with reduced ejection fraction (HFrEF) in the Philippines. 
The results of the trial showed that dapagliflozin adds to other guideline-recommended therapies in reducing the risk of mortality and heart failure hospitalization. It also improves symptoms in patients with HFrEF.
A total of 4,744 patients 22 to 94 years of age with a mean age of 66.3 years were randomized for the trial.  The benefit of dapagliflozin was found consistent in both older and younger patients.
“Patients with a history of recurrent urinary tract infection or genital infection should be careful [when taking dapagliflozin],” said Dr. David K. Sim, president of Singapore’s Heart Failure Society, in response to a question about the medication’s contraindications during a February 16 discussion organized by AstraZeneca ....

The Philippines , Erlynp Demerre , Davidk Sim , Patriciab Mirasol , Luke Medical Center , Heart Failure Program At St , Department Of Health , Singapore Heart Failure Society , Drug Administration , Heart Failure Society , Southeast Asia , Heart Failure Program , Medical Center , Quezon City , தி பிலிப்பைன்ஸ் , லூக் மருத்துவ மையம் , இதயம் தோல்வி ப்ரோக்ர்யாம் இல் ஸ்டம்ப் , துறை ஆஃப் ஆரோக்கியம் , சிங்கப்பூர் இதயம் தோல்வி சமூகம் , இதயம் தோல்வி சமூகம் , தென்கிழக்கு ஆசியா , இதயம் தோல்வி ப்ரோக்ர்யாம் , மருத்துவ மையம் , கயீஸந் நகரம் ,